Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 1, 2026

Conditions
Type 2 Diabetes
Interventions
DRUG

Cofrogliptin+SGLT2i+Metformin

The cofrogliptin add-on group will continue their existing SGLT2i plus metformin regimen and dosing, with the add-on of cofrogliptin over 24 weeks of triple combined therapy.

DRUG

Metformin dose escalation

The metformin dose escalation group will have their metformin dose gradually increased to the target dose.

Trial Locations (1)

Unknown

RECRUITING

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Ningbo Medical Center Lihuili Hospital

OTHER_GOV

collaborator

Hangzhou Traditional Chinese Medicine Hospital

UNKNOWN

collaborator

Wenzhou Central Hospital

OTHER

collaborator

The Second Affiliated Hospital of Dalian Medical University

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER